Soligenix announces board of directors appointments

Late-stage pharmaceutical company Soligenix, Inc., has announced several appointments to its board of directors.
 
The appointments include Jerome Zeldis, the chief executive officer of Celgene Global Health and chief medical officer of Celgene Corporation, and Keith Brownlie, a former partner at Ernst & Young.

Soligenix is a company that develops products to treat life-threatening side effects of cancer treatments and vaccines for certain bioterrorism agents, including RiVAX, which is designed to protect against the lethal effects of ricin toxin exposure.
 
"We are delighted to be able to attract the caliber of these two biotechnology industry veterans to the Soligenix Board," Christopher J. Schaber, the president and CEO of Soligenix, said. "As Soligenix looks to advance its pipeline, we intend to leverage Jerry Zeldis' experience in helping to grow a very successful company like Celgene into the multibillion dollar, multinational biotechnology company that it is today. Additionally, we are pleased to identify Keith Brownlie, with his wealth of financial expertise in the life science industry, to serve as chairman of our audit committee. Both of these individuals have outstanding records of achievement in their respective fields and we believe they will add significantly to our already diverse and experienced Board of Directors and management team.  We look forward to their contributions to our future success, particularly as we get closer to the expected completion of our confirmatory Phase 3 trial of orBec for the treatment of acute GI GVHD later this year."